Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company's financial performance shows a significant decline in revenue and increased cash burn, despite a reduced net loss. The Q&A section highlights uncertainties with AbbVie milestones and unclear management responses, adding to investor concerns. Additionally, the cash runway suggests potential liquidity issues. These factors, combined with competitive pressures and regulatory risks, likely lead to a negative stock price reaction.
Q4 2024 Revenue $164,000 (down from $299,000 in Q4 2023), decrease mainly related to sales of RH collagen product.
2024 Annual Revenue $515,000 (down from $11 million in 2023), decrease primarily due to a $10 million milestone payment received in 2023 from the AbbVie agreement.
Q4 2024 Cost of Revenue $272,000 (down from $773,000 in Q4 2023), decrease mainly due to $312,000 in royalty expenses related to the AbbVie milestone payment and a decrease of $324,000 in bioink and RH collagen sales.
2024 Annual Cost of Revenue $1.6 million (down from $2 million in 2023), decrease mainly due to $312,000 in royalty expenses and a decrease in sales, offset by $247,000 related to inventory impairment.
Q4 2024 Gross Loss $108,000 (down from $474,000 in Q4 2023), reflecting lower revenue.
2024 Annual Gross Loss $1.1 million (down from a gross profit of $9 million in 2023), primarily due to the significant milestone payment received in 2023.
Q4 2024 Operating Expenses $3.9 million (down from $4.6 million in Q4 2023), decrease mainly due to $303,000 reduction in employee salaries and share-based compensation, and $386,000 decrease in R&D activity.
2024 Annual Operating Expenses $16.1 million (down from $16.5 million in 2023), decrease mainly due to lower general administrative and marketing expenses.
Q4 2024 Financial Income Net $96,000 (down from $379,000 in Q4 2023), decrease attributed to lower financial income.
2024 Annual Financial Income Net $642,000 (up from $493,000 in 2023), increase due to exchange rate differences.
Q4 2024 Net Loss $3.9 million or $0.34 per share (down from $4.7 million or $0.41 per share in Q4 2023), improvement due to lower operating expenses.
2024 Annual Net Loss $16.6 million or $1.45 per share (up from $7 million or $0.62 per share in 2023), increase primarily due to the $10 million milestone payment received in 2023.
Cash and Cash Equivalents $11.9 million as of December 31, 2024, expected to satisfy operational requirements through Q2 2026.
Cash Used in Operating Activities $14.1 million (up from $2.8 million in 2023), increase due to higher operational costs.
Cash Used in Investing Activities $539,000 (down from $1.2 million provided in 2023), related to property and equipment purchases.
Cash Provided by Financing Activities $9,000 (down from $1.1 million in 2023), decrease due to absence of warrant exercise proceeds.
Photocurable Dermal Filler: In preclinical phase, targeting a market valued at $6.3 billion with a 10% CAGR. Positive feedback from leaders in aesthetic medicine.
Regenerative Breast Implant: Advancing preclinical testing of 250cc commercial-sized implants. Promising outcomes observed with no complications and maintained mechanical properties.
Collaboration with AbbVie: Ongoing development of dermal and soft tissue filler product. AbbVie is reviewing interim results from clinical trials initiated in 2023.
Cost of Revenues: GAAP cost of revenues decreased to $272,000 in Q4 2024 from $773,000 in Q4 2023.
Operating Expenses: GAAP operating expenses decreased to $3.9 million in Q4 2024 from $4.6 million in Q4 2023.
Cash Position: Cash and cash equivalents as of December 31, 2024, were $11.9 million, expected to cover operational requirements through Q2 2026.
Revenue Decrease: Revenue for Q4 2024 was $164,000, down from $299,000 in Q4 2023, primarily due to reduced sales of RH collagen products.
GAAP Revenue Decline: GAAP revenue for the year ended December 31, 2024, was $515,000, significantly lower than $11 million in 2023, largely due to a $10 million milestone payment received in 2023.
Operating Loss: GAAP net loss for Q4 2024 was $3.9 million, compared to a net loss of $4.7 million in Q4 2023, indicating ongoing financial challenges.
Cash Burn Rate: Cash used in operating activities increased to $14.1 million in 2024 from $2.8 million in 2023, highlighting a significant rise in operational costs.
Cash Runway: The current cash balance of $11.9 million is projected to sustain operations through the second quarter of 2026, indicating potential liquidity risks if revenue does not improve.
Regulatory Risks: The company is engaged in preclinical and clinical studies, which carry inherent regulatory risks that could impact product development timelines and market entry.
Competitive Pressures: The aesthetic medicine market is highly competitive, and the success of CollPlant's products will depend on their ability to differentiate from existing offerings.
Photocurable Dermal Filler Candidate: In preclinical phase, targeting a market valued at approximately $6.3 billion with a 10% CAGR. Positive feedback from leaders in aesthetic medicine.
Collaboration with AbbVie: Focus on developing a dermal and soft tissue filler product. AbbVie is currently reviewing interim results from clinical trials initiated in 2023.
Regenerative Breast Implant: Advancing preclinical testing of commercial-sized breast implants. Promising outcomes observed with no complications reported.
Recombinant Human Collagen Technology: Continuous demand for bioink and other applications, with interest from various companies.
Revenue Expectations: GAAP revenue for Q4 2024 was $164,000, down from $299,000 in Q4 2023. Yearly revenue was $515,000 compared to $11 million in 2023.
Cash Runway: Cash and cash equivalents as of December 31, 2024, were $11.9 million, expected to satisfy operational requirements through Q2 2026.
Operating Expenses: GAAP operating expenses for Q4 2024 were $3.9 million, down from $4.6 million in Q4 2023.
Net Loss: GAAP net loss for Q4 2024 was $3.9 million, or $0.34 per share, compared to a net loss of $4.7 million, or $0.41 per share in Q4 2023.
Shareholder Return Plan: CollPlant Biotechnologies Ltd. received a $2 million payment from AbbVie during Q1 2025, following a development achievement under their agreement.
The company's financial performance shows a significant decline in revenue and increased cash burn, despite a reduced net loss. The Q&A section highlights uncertainties with AbbVie milestones and unclear management responses, adding to investor concerns. Additionally, the cash runway suggests potential liquidity issues. These factors, combined with competitive pressures and regulatory risks, likely lead to a negative stock price reaction.
Despite some positive developments, such as the collaboration with AbbVie and cash management strategies, the overall financial performance is weak, with declining revenues and increased net losses. The lack of clear guidance from management, combined with regulatory risks and competitive market pressures, further contribute to a negative sentiment. The Q&A session highlighted uncertainties about future milestone payments and revenue streams, adding to investor concerns. These factors suggest a negative stock price reaction in the near term.
The earnings call reveals a mixed picture: while there are some positives, such as a payment from AbbVie and reduced operating expenses, the financial performance is concerning. Revenue has significantly decreased, there's a high cash burn rate, and the net loss has increased. The absence of detailed guidance and potential regulatory and competitive risks further weigh negatively. The market reaction is likely to be negative as the financial outlook appears weak, with uncertainties around future revenue and milestone payments.
The financial performance shows a significant revenue decline and increased net losses, primarily due to the absence of milestone payments. Despite positive preclinical study results and ongoing partnerships, the lack of immediate new agreements and the focus on securing non-dilutive cash suggest operational and funding challenges. The Q&A section reveals uncertainty about future agreements, which could unsettle investors. The company's operational efficiency improvements are overshadowed by financial struggles, leading to a negative sentiment likely affecting the stock price in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
